Business
Kyowa Kirin Premiers New CTCL Staging Tool for Healthcare Providers
First-of-its kind tool to guide HCPs on what to consider when staging patients with Mycosis Fungoides and Sézary SyndromePRINCETON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the launch of a new tool to help healthcare providers (HCPs) navigate the complicated process of accurately staging patients with Mycosis Fungoides (MF) or Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL). The
About this update from Kyowa Kirin Co., Ltd.
[{"type":"image","alt":"Kyowa Kirin","displaySize":"","headline":null,"caption":"Kyowa Kirin","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/b9c3225d04b222adf60766e494f98867"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/K77r3CFldRtJVVNCB0.bKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b9c3225d04b222adf60766e494f98867","width":300,"height":58}},"lazy":false},{"type":"text","content":"First-of-its kind tool to guide HCPs on what to consider when staging patients with Mycosis Fungoides and Sézary Syndrome","length":121,"tagName":"p"},{"type":"text","content":"PRINCETON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Kyowa Kirin, Inc. a wholly owned subsidiary of Kyowa Kirin Co. Ltd, today announced the launch of a new tool to help healthcare providers (HCPs) navigate the complicated process of accurately staging patients with Mycosis Fungoides (MF) or Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL). The tool is now live on PROBEinCTCL.com alongside comprehensive information and resources about CTCL.","length":476,"tagName":"p"},{"type":"text","content":"“CTCL is a rare form of blood cancer that first appears on the skin, presenting acute challenges in its diagnosis. In fact, many patients go 2-7 years before receiving an accurate diagnosis,” says Dr. Pamela Allen, MD, a board-certified hematologist. Dr. Allen is one of several physicians who consulted with Kyowa Kirin on the tool’s development. “While clinical judgment is irreplaceable, a user-friendly tool that walks clinicians through each step of CTCL staging can be invaluable. By translating complex guidelines into a practical, compartment-by-compartment assessment, the tool aims to simplify a challenging process and support more consistent, informed care.”","length":670,"tagName":"p"},{"type":"text","content":"Simplifying CTCL StagingThrough a combination of up to 20 Yes/No questions paired with real clinical case imagery, the Staging Tool brings HCPs through the TNMB system, which evaluates the extent of disease across 4 compartments: skin (T), lymph nodes (N), visceral/metastasis (M), and blood (B). Upon completion, users are shown a staging which aligns most closely with the patient case provided and are directed to additi...